Last checked at 27 Sep 2021 15:18
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Director Dealing
Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that it was notified on 27 September 2021 that on that same day, Nick Rodgers, Chairman of the Company, purchased 2,100 Ordinary Shares at a price of 119.7999p per Ordinary Share. Following the transaction his total beneficial interest is 56,073 Ordinary Shares, representing 0.09% of the total issued share capital of the Company.
The above purchase of shares is pursuant to the award of a 2020 bonus to Mr. Rodgers, payable in Destiny Pharma shares (on a net of tax basis). The bonus is payable in two equal tranches following the announcement of the Company' 2020 annual results and 2021 interim results.
Details of the full notification received by the Company are set out below:
1. | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Nick Rodgers |
2. | Reason for the Notification | |
a) | Position/status | Chairman |
b) | Initial notification/Amendment | Initial notification |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Destiny Pharma plc |
b) | LEI | 213800O9WH9Z38EHAC95 |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1 pence each in Destiny Pharma Plc |
Identification code | DEST GB00BDHSP575 | |
b) | Nature of the transaction | Purchase of Ordinary Shares |
c) | Price(s) and volume(s) | 119.7999 pence per Ordinary Share 2,100 Ordinary Shares |
d) | Aggregated information: Aggregated volume Price |
See 4c) above
|
e) | Date of the transaction | 27 September 2021 |
f) | Place of the transaction | London Stock Exchange, AIM Market |
Enquiries:
Destiny Pharma plc | +44 (0) 1273 704 440 |
Neil Clark (Chief Executive Officer)Shaun Claydon (Chief Financial Officer and Company Secretary) | |
finnCap Limited - Nominated Adviser and Joint Broker | +44 (0) 20 7220 0500 |
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)Alice Lane (ECM) | |
WG Partners LLP - Joint Broker | +44 (0) 20 3705 9330 |
Nigel Barnes / Claes Spång / Nigel Birks | |
Optimum Strategic Communications | +44 (0) 203 174 1789 |
Mary Clark / Hollie Vile / Manel Mateus | |
MC Services AG | |
Anne Hennecke / Andreas Burckhardt | +49-211-529252-0 |
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com